Image 2_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Multifactorial analysis showed that MELD score >18 and increased total bilirubin (TBIL) levels within one week were significant risk factors for OS. Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Table 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Multifactorial analysis showed that MELD score >18 and increased total bilirubin (TBIL) levels within one week were significant risk factors for OS. Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Image 3_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Multifactorial analysis showed that MELD score >18 and increased total bilirubin (TBIL) levels within one week were significant risk factors for OS. Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Image 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Multifactorial analysis showed that MELD score >18 and increased total bilirubin (TBIL) levels within one week were significant risk factors for OS. Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

MO-SAM segmentation performance using the Grid method in the forested landscape. by Qitong Wang (15279695)

LNd stimulate LPN to form a circadian feedback circuit. by Xin Yuan (174619)

NPF-NPFR pathway in LNd-LPN feedback circuit fine-tune cooling induced locomotion increase. by Xin Yuan (174619)

Data Sheet 1_Global burden, trends and inequalities of maternal hypertensive disorders among reproductive-age women of advanced maternal age, 1990–2021: a population-based study.pd... by Xuanyu Zhao (5881895)

“…Background<p>Maternal hypertensive disorders (MHD) are leading causes of maternal morbidity and mortality worldwide, particularly among reproductive-age women of advanced maternal age (AMA), representing a significant global public health challenge.…”

The circadian LPN promote sleep through AstC pathway. by Xin Yuan (174619)

AC-LPN circuit control high temperature induced increase of evening sleep. by Xin Yuan (174619)

Release kinetics of GDNF from SIS with and without syndecan-3 (SDC3) added. by Shiu-Jau Chen (21077803)

Engineering an Electrospun Composite Ureteral Stent Based on PLGA with Antibacterial Properties and Tailored Mechanical Strength by Halah Hadi Salih (20758553)

“…Mechanical properties noticeably decreased after 4 weeks. The designed stent material exhibited excellent in vitro biocompatibility, significant antibacterial activity against Staphylococcus aureus and Escherichia coli, and suitable in vitro biodegradability. …”

Data Sheet 1_Remarkable tumor response to Iruplinalkib in a 14-year-old girl with ALK-positive advanced metastatic non–small-cell lung cancer: a case report.pdf by Jiahao Wang (4710915)

“…Most metastatic lesions also showed significant regression. By six months, the pulmonary tumor had almost disappeared. …”

Application to actual brain network functional states. by Remy Ben Messaoud (20521877)

Table 1_Relationship between advanced lung cancer inflammation index and all-cause and cause-specific mortality among chronic inflammatory airway diseases patients: a population-ba... by Zhuanbo Luo (378365)

“…An elevated ALI was significantly related to a decreased risk of all-cause mortality, as well as mortality from cardiovascular and respiratory diseases among CIAD patients. …”

Table 1_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”

Table 5_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”

Table 4_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”

Table 2_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”

Table 3_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”